After 2010, thanks to the introduction of a new IgG3-specific tryptophan column for IA therapy in patients with DCM-related advanced HF, this previously non-selective IA method became semi-selective regarding its ability to remove β1AR-AAbs [148]. This evidence concerns the gene IGHG3 and hydrops fetalis.